Dr. Reddy’s Laboratories. File
| Photo Credit: The Hindu
Dr. Reddy’s Laboratories has decided to delay commercial supplies of semaglutide due to an issue associated with the active pharmaceutical ingredient (API) used in the drug, an announcement on Thursday (July 9, 2026) that saw the generic drugmaker’s shares plunge.“Certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient used in the product. Until the issue is resolved, commercial supplies of the product will be delayed for a certain period of time,” Dr. Reddy’s said.It is investigating the root cause and taking appropriate measures to ensure product quality. There is no impact on patient safety or on the product’s existing global regulatory filings, the company said in a filing.“We remain committed to ensuring reliable global supplies of this important metabolic therapy,” Dr. Reddy’s said.Semaglutide is the active ingredient in Danish major Novo Nordisk’s blockbuster diabetes and weight loss drugs Wegovy and Ozempic. Dr. Reddy’s was among the clutch of drugmakers in India who rolled out their versions of the drug soon after the patent on Semaglutide expired in March 2026.Dr Reddy’s had followed up the launch of its generic Semaglutide injection Obeda for Type 2 diabetes with the rollout of a semaglutide biosimilar in tablet form under the same brand in May. “With this launch, we are broadening our GLP‑1 portfolio. As the product is developed and formulated in-house, we are committed to reliable supply and consistent quality for patients in India,” CEO-Global Generics M.V. Ramana had said.Dr. Reddy’s shares were 5.24% down around 12.30 p.m. at ₹1,278 apiece on the BSE. The company said it will host a conference call on Thursday evening to discuss the development. Published - July 09, 2026 12:39 pm IST
